



# Test Definition: MPNML

MPL Exon 10 Sequencing, Reflex, Varies

## Overview

### Useful For

Aiding in the distinction between a reactive cytosis and a myeloproliferative neoplasm when *JAK2* V617F testing result is negative

Evaluates for variants in *MPL* in an algorithmic process for MPNCM / Myeloproliferative Neoplasm, *CALR* with Reflex to *MPL*, Varies

### Method Name

Only orderable as a reflex. For more information see MPNCM / Myeloproliferative Neoplasm, *CALR* with Reflex to *MPL*, Varies.

Sanger Sequencing

### NY State Available

Yes

## Specimen

### Specimen Type

Varies

### Specimen Required

Only orderable as a reflex. For more information see MPNCM / Myeloproliferative Neoplasm, *CALR* with Reflex to *MPL*, Varies.

### Reject Due To

Gross hemolysis	Reject
Paraffin-embedded bone marrow aspirate clot or biopsy blocks Slides Paraffin shavings Moderately to severely	Reject

clotted	
---------	--

## Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Varies		

## Clinical & Interpretive

### Clinical Information

The *JAK2* V617F variant is present in 95% to 98% of patients with polycythemia vera, 50% to 60% of patients with primary myelofibrosis (PMF), and 50% to 60% of patients with essential thrombocythemia (ET). Detection of the *JAK2* V617F helps establish the diagnosis of a myeloproliferative neoplasm (MPN). However, a negative *JAK2* V617F result does not indicate the absence of MPN. Other important molecular markers in *BCR::ABL1*-negative MPN include *CALR* exon 9 alterations (20%-30% of PMF and ET) and *MPL* exon 10 alterations (5%-10% of PMF and 3%-5% of ET). Variants in *JAK2*, *CALR*, and *MPL* are essentially mutually exclusive. A *CALR* variant is associated with decreased risk of thrombosis in both ET and PMF and confers a favorable clinical outcome in patients with PMF. A triple negative (*JAK2* V617F, *CALR*, and *MPL*-negative) genotype is considered a high-risk molecular signature in PMF.

### Reference Values

Only orderable as a reflex. For more information see MPNCLM / Myeloproliferative Neoplasm, *CALR* with Reflex to *MPL*, Varies.

An interpretive report will be provided.

### Interpretation

The results will be reported as 1 of the 3 following states:

- Positive for *CALR* variant
- Positive for *MPL* variant
- Negative for *CALR* and *MPL* variants

Positive variant status is highly suggestive of a myeloid neoplasm and clinicopathologic correlation is necessary in all cases.

Negative variant status does not exclude the presence of a myeloproliferative neoplasm or other neoplasms.

### Cautions

A positive result is not specific for a particular subtype of myeloproliferative neoplasm and clinicopathologic correlation is necessary in all cases.

A negative result does not exclude the presence of a myeloproliferative neoplasm or other neoplastic process.

### Clinical Reference

1. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutation of calreticulin in myeloproliferative neoplasms. *N*

Engl J Med. 2013;369(25):2379-2390

2. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutation in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405

3. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552-1555

4. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472-1477

5. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270

6. Pardanani AD, Levine RL, Lasho T, et al. *MPL*515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-3476

## Performance

### Method Description

Genomic DNA is extracted, and Sanger sequencing is used to evaluate for alterations in *MPL*, exon 10. The sensitivity of this assay is approximately 20%, such that samples containing lower percentages of altered DNA will appear negative. (Unpublished Mayo method)

### PDF Report

No

### Day(s) Performed

Monday through Friday

### Report Available

7 to 10 days

### Specimen Retention Time

Extracted DNA: 3 months

### Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Main Campus

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

### Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

81339-MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), exon 10 sequence